Shots:

• The approval is based on efficacy and safety data from the clinical development program- including two P- III TULIP trials and the P-II MUSE trial evaluating Saphnelo vs PBO in patients with SLE who are receiving standard therapy
• The result from the trials showed a reduction in overall disease activity across organ systems- including skin and joints- and achieved a sustained reduction in OCS with both groups receiving standard therapy
• Saphnelo is a mAb that binds to subunit 1 of the type I IFN receptor- further blocks the activity of type I IFNs and is under regulatory review for SLE in the EU and Japan. This marks the first regulatory approval for a type I IFN receptor antagonist for SLE

 to   | Ref: AstraZeneca | Image: Mint